TTP Diagnosis and Management
Diagnose TTP by measuring ADAMTS-13 activity <10% in patients presenting with thrombocytopenia and microangiopathic hemolytic anemia, and immediately initiate treatment with therapeutic plasma exchange, corticosteroids, and caplacizumab without waiting for ADAMTS-13 results 1.
Diagnostic Approach
Clinical Recognition
Suspect TTP when patients present with:
- Severe thrombocytopenia (typically <30 × 10⁹/L)
- Microangiopathic hemolytic anemia with:
- Low hemoglobin/hematocrit
- Elevated lactate dehydrogenase
- Schistocytes on blood smear
- Variable end-organ damage (neurologic, renal, cardiac) 1
Critical pitfall: The classic "pentad" (thrombocytopenia, hemolytic anemia, neurologic changes, renal dysfunction, fever) is present in only a minority of cases. Do not wait for all five features 2.
Rapid Risk Stratification
Before ADAMTS-13 results are available, use clinical scoring systems:
- French score or PLASMIC score to assess likelihood of severe ADAMTS-13 deficiency 1
- These tools help triage patients for immediate treatment while awaiting confirmatory testing
Confirmatory Testing
ADAMTS-13 activity <10 IU/dL (or <10% of normal) is the diagnostic gold standard 1, 3.
Differentiate subtypes:
- Immune TTP (iTTP): Positive anti-ADAMTS-13 IgG antibodies/inhibitors
- Congenital TTP (cTTP): Negative antibodies on repeated testing + ADAMTS13 gene mutations (approximately 250 known mutations) 1
Important caveat: Absence of detectable anti-ADAMTS-13 antibodies during acute episodes does NOT rule out iTTP, as free antibodies may be undetectable by ELISA due to immune complex formation or accelerated clearance. Repeat antibody testing after therapy and consider genetic testing if persistently negative 1.
Treatment Strategy
Immune TTP (iTTP) - Acute Episode
First-line therapy (start immediately upon clinical suspicion) 1, 4:
Therapeutic plasma exchange (TPE): Daily sessions until platelet recovery
- Reduces mortality from 15.7% to 3.9% compared to plasma infusion alone 4
Corticosteroids: High-dose therapy concurrent with TPE
Caplacizumab: Anti-VWF A1 domain nanobody that blocks platelet-VWF binding
- Add to TPE and corticosteroids
Rituximab: Upfront administration to suppress autoantibody production
- Standard treatment combining all four modalities reduced mortality to 2.2% vs. 12.2% in historical controls 4
The 2025 ISTH guidelines reviewed new evidence supporting caplacizumab's therapeutic efficacy and potential survival benefit but concluded no changes to the 2020 recommendations were warranted 1.
Congenital TTP (cTTP) - Maintenance Therapy
For patients in remission, the 2025 ISTH guidelines issued a strong new recommendation 1:
Use recombinant ADAMTS-13 over fresh frozen plasma (moderate certainty evidence)
- Provides superior efficacy in preventing acute episodes
- Reduces treatment burden
- Fewer adverse events compared to plasma therapy 1, 5
If recombinant ADAMTS-13 is unavailable: Use fresh frozen plasma over watch-and-wait approach (very low certainty evidence) 1
Acute cTTP Episodes
- Treat with plasma infusions or recombinant ADAMTS-13 to supplement enzyme activity
- Episodes often require a "second hit" trigger (infection, pregnancy, surgery) 5
Follow-Up Management
Monitoring Strategy
- Regular ADAMTS-13 activity monitoring in remission
- Preemptive rituximab at biochemical relapse (rising antibody titers, falling ADAMTS-13) to prevent clinical recurrence 6
- Screen for late sequelae: cardiovascular disease, chronic kidney disease, neurocognitive impairments 5
Pregnancy Management
- Increased monitoring and recurrence prophylaxis recommended for female TTP patients 4
- Pregnancy is a known trigger for both iTTP relapse and cTTP episodes
Key Clinical Pitfalls
Do not delay treatment waiting for ADAMTS-13 results—turnaround time can be several days, and mortality risk is immediate 2
Do not rely on the pentad—most patients present with incomplete features 2
Do not assume negative antibodies rule out iTTP during acute episodes—repeat testing after treatment 1
Distinguish TTP from other TMAs (pregnancy-associated, infection-related, drug-induced, malignancy-associated)—only 6% of TMA cases are primary TTP 2
Shared decision-making should include discussion of benefits, harms, and treatment burden, particularly when choosing between recombinant ADAMTS-13 and plasma therapy for cTTP 1